Evidence map›Paper›PMID 24518104›Full record

ArticleScientific reports2014

Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey.

Claudia Pansieri, Chiara Pandolfini, Valery Elie, Mark A Turner, Sailesh Kotecha, Evelyne Jacqz-Aigrain, Maurizio Bonati

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02282176 (A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Preterm Infants), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02282176 phase3withdrawnnot on this mapstarted 2015, after this paper: background citation

A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Preterm Infants

TypeinterventionalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2015 to 2018Enrolled0ConditionsBronchopulmonary DysplasiaArmsAzithromycin, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. [Advances in clinical pharmacotherapy for neonatalZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  2. Article
  3. Azithromycin for Eradication ofThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Claudia PansieriDepartment of Public Health, Laboratory for Mother and Child Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156, Milan, Italy.
Chiara PandolfiniDepartment of Public Health, Laboratory for Mother and Child Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156, Milan, Italy.
Valery ElieService de Pharmacologie Pédiatrique, AP-HP, Hôpital Robert Debré, 48 boulevard Serurier, 75019 Paris, France.
Mark A TurnerDepartment of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK.
Sailesh KotechaDepartment of Child Health, Cardiff University School of Medicine, Cardiff CF14 4XN, UK.
Evelyne Jacqz-AigrainService de Pharmacologie Pédiatrique, AP-HP, Hôpital Robert Debré, 48 boulevard Serurier, 75019 Paris, France.
Maurizio BonatiDepartment of Public Health, Laboratory for Mother and Child Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156, Milan, Italy.
Cardiff University · GBLiverpool Women's Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A survey was set up to gauge the opinions of neonatologists on the role of Ureaplasma in bronchopulmonary dysplasia (BPD) development, the use of azithromycin for BPD prevention, and the factors influencing azithromycin use in European neonatal intensive care units (NICUs). 167 NICUs participated in the survey, representing 28 European countries. For respondents, the two major perceived risk factors for BPD were prematurity of <28 weeks and high oxygen requirements. Only 38% of NICUs had a protocol for BPD prevention and 47% routinely tested for Ureaplasma. In cases of infection, macrolides were the first choice. Most (78%) NICUs were interested in participating in a trial evaluating azithromycin safety and efficacy in reducing BPD rates. Opinions and clinical practice varied between European neonatal units, and differences in Ureaplasma treatment and prevention of BPD highlight the need for further azithromycin evaluation and for improved therapeutic knowledge in preterms.

Indexed as

Anti-Bacterial AgentsAzithromycinBronchopulmonary DysplasiaData CollectionEuropeHumansInfant, NewbornInfant, PrematureIntensive Care Units, NeonatalRisk FactorsSurveys and QuestionnairesUreaplasmaUreaplasma InfectionsAnti-Bacterial AgentsAzithromycin

Identifiers

PMID24518104
PMCPMC5379254
OpenAlexW2079869246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.